Bristol Myers Announces 'Encouraging' Response with Opdivo Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003
Paul Quintaro